Grifols, S.A. (NASDAQ:GRFS) Short Interest Update

Grifols, S.A. (NASDAQ:GRFS) was the recipient of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 2,710,000 shares, a decline of 28.9% from the February 28th total of 3,810,000 shares. Currently, 1.1% of the company’s shares are short sold. Based on an average trading volume of 991,800 shares, the days-to-cover ratio is presently 2.7 days.

Institutional Trading of Grifols

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of Grifols by 44.5% in the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,527 shares during the last quarter. HighTower Advisors LLC lifted its holdings in Grifols by 12.5% in the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 1,546 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Grifols by 5.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company’s stock valued at $247,000 after acquiring an additional 1,657 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Grifols by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 25,867 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 2,403 shares during the period. Finally, R Squared Ltd bought a new position in shares of Grifols in the 4th quarter worth about $28,000.

Grifols Trading Down 2.0 %

GRFS traded down $0.15 during midday trading on Tuesday, hitting $6.97. 833,419 shares of the company were exchanged, compared to its average volume of 1,229,624. The firm’s 50 day moving average price is $7.56 and its 200-day moving average price is $8.03. Grifols has a 1-year low of $5.79 and a 1-year high of $9.96. The firm has a market capitalization of $4.79 billion, a P/E ratio of 5.95 and a beta of 0.35. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11.

Wall Street Analyst Weigh In

Separately, Morgan Stanley initiated coverage on shares of Grifols in a research note on Wednesday, February 12th. They set an “overweight” rating for the company.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.